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Abstract
Background—The Coronary Psychosocial Evaluation Studies (COPES) trial demonstrated
promising results for enhanced depression treatment to reduce cardiovascular risk of patients with
acute coronary syndrome and comorbid depression, but the long-term effectiveness of this
intervention is unclear.
Methods—157 participants with persistent depression after hospitalization for acute coronary
syndromes were enrolled in the COPES trial. 80 participants were allocated to 6-months of
enhanced depression treatment, and 77 were allocated to usual care. We report on an additional 12
months of observational follow-up for the composite outcome of death or first hospitalization for
myocardial infarction or unstable angina.
Results—Although the intervention was previously shown to have favorable cardiovascular
effects during the treatment period, we observed a significant time-by-treatment group interaction
during extended follow-up (p=0.008). Specifically, during the 6-month treatment period, death or
hospitalization for myocardial infarction / unstable angina occurred in 3 (4%) participants in the
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treatment group, compared with 11 (14%) in the usual care group (HR=0.25, 95% confidence
interval [CI] 0.07-0.90, p=0.03). In contrast, during 12 months of additional observational follow-
up, 11 (14%) participants in the treatment group experienced the composite outcome, as compared
to 3 (4%) in the usual care group (HR=2.91, 95% CI 0.80-10.56, p=0.10).
Conclusions—Enhanced depression treatment was associated with a reduced risk of death or
hospitalization for myocardial infarction / unstable angina during active treatment, but this effect
did not persist after treatment ceased. Future research is needed to confirm our findings, and to
determine the optimal duration of depression treatment in patients with depression after acute
coronary syndromes.
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Introduction
Depression is associated with increased risk for death and major adverse cardiac events in
patients with coronary heart disease (1). Prior trials of brief depression treatment have failed
to demonstrate long-term benefits on cardiovascular outcomes (2, 3). In the Coronary
Psychosocial Evaluation Studies (COPES) randomized controlled trial, we have previously
reported that patient-preference based, enhanced depression treatment compared to usual
care in patients with acute coronary syndromes may reduce the risk of death or major
adverse cardiac events during the 6-months treatment period (4). To address whether this
treatment effect was durable when active treatment ended, we examined cardiac events and
mortality in the COPES trial through an additional 12 months of observational follow-up
after the end of the 6-month treatment period.
Methods
As previously described (4), 157 patients with a score of ≥10 on the Beck Depression
Inventory (5) within 1 week of acute coronary syndrome hospitalization and again at 3-
month follow-up were recruited from January 1, 2005, through February 29, 2008. Patients
were randomized to either usual care or to enhanced depression treatment involving stepped,
patient-preference driven care with problem-solving therapy, pharmacotherapy, or both.
Demographic data and medical history were collected at index hospitalization. During the 6-
month treatment period and for an additional 12 months after treatment ended,
hospitalization information was collected for all patients, and hospital systems were
surveyed actively for hospitalizations of trial participants. Hospitalization records were
adjudicated in a blinded fashion by two cardiologists to determine occurrences of major
adverse cardiac events, defined as nonfatal myocardial infarction or hospitalization for
unstable angina; a third cardiologist resolved disagreements. The National Death Index was
searched to confirm reported deaths and to determine vital status of those who could not be
contacted.
For this analysis, we constructed Cox proportional hazards models to estimate the effect of
enhanced depression treatment on time–to-death or first major adverse cardiac event,
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adjusted for age, sex, Global Registry of Acute Coronary Events risk score (6), and left
ventricular ejection fraction. Because a formal significance test based on scaled and
unscaled Schoenfeld residuals confirmed that the treatment effect differed between the
treatment and the observational follow-up time periods (p=0.008),(7) treatment assignment
was entered in the model as a time-varying covariate, with separate estimates reported for
the effect of enhanced depression treatment during the 6-month intervention period and for
the 12-month subsequent observational follow-up.
Results
Of the 157 participants with persistent depressive symptoms 3 months after an index acute
coronary syndrome hospitalization, 80 were randomized to enhanced depression treatment
and 77 were randomized to usual care (Figure 1), as has been reported previously.(4) There
was no significant difference between the two groups with regards to age, sex, race,
ethnicity, education level, marital status, baseline Beck Depression Inventory score, Global
Registry of Acute Coronary Events risk score, revascularization status during index
hospitalization, or left ventricular ejection fraction (Table 1).
The median follow-up period was 11.8 months after treatment ended. During the 6-month
intervention period, 11 (14%) participants in the usual care arm experienced the composite
outcome of death or hospitalization for myocardial infarction / unstable angina, including
one participant whose death was not identified in our previously published analysis.(4) In
comparison, 3 (4%) participants experienced the composite outcome in the intervention arm
during the intervention period (HR=0.25, 95% confidence interval [CI] 0.07-0.90, p=0.03).
At the beginning of the 12-month observational follow-up period, 58 of 77 (75%) patients in
the control group had Beck Depression Inventory score of ≥10, compared to 46 of 80 (58%)
patients in the intervention group (p=0.018), suggesting that a substantial number of
participants continued to have depressive symptoms. During this time period, 3 (4%)
participants in the usual care arm experienced the composite outcome of death or
hospitalization for myocardial infarction / unstable angina, while 11 (14%) participants in
the intervention arm had the composite outcome (HR=2.91, 95% CI 0.80-10.56, p=0.10)
(Table 2 and Figure 2).
Discussion
During the observational follow-up of the COPES randomized controlled trial, we found that
the original finding of a reduced risk of death or hospitalization for myocardial infarction /
unstable angina during the 6-month treatment period did not persist after treatment ended.
Furthermore, there was a significant time-treatment interaction in the opposite direction,
suggesting that there may have been a “catch-up” in cardiovascular events after the
intervention ended. To our knowledge, this is the first report of a “catch-up” phenomenon
concerning cardiac events after the end of depression treatment, with implications for future
trials of depression management in patients with coronary heart disease.
Recent trials of novel depression interventions in this patient population have mainly
examined the effect of interventions during the period in which depression treatment is
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offered. In a trial of 214 participants from 14 primary care clinics, Katon and colleagues
showed that a stepped, patient-preference based intervention led to improvements in both
depressive symptoms and management of coronary heart disease, compared to usual care,
during the 12-months treatment period.(8) Similarly, Blumenthal and colleagues recently
reported that for patients with coronary heart disease and elevated depressive symptoms, a
4-month structured exercise intervention improved heart rate variability, a marker of cardiac
risk, as compared to those receiving sertraline or placebo, at the end of the 4-month period.
(9) However, as the current findings suggest, the extent to which the benefits reported in
these studies will persist after the completion of the interventions tested cannot be assumed.
Future trials targeting depression in coronary heart disease patients may need to consider
longer treatment duration, as well as evaluate the benefits and costs of ongoing symptom
monitoring and “booster” treatments.
There are several potential mechanisms for the “catch up” phenomenon in cardiac risk that
we observed. Depression is associated with biological processes, such as inflammation and
endothelial dysfunction,(10-12) and behavioral processes, such as smoking and physical
inactivity,(13) that are known to contribute to worse outcomes after hospitalizations for
acute coronary syndromes. A 6-month course of depression treatment may not be sufficient
to permanently affect these pathways, or may be too brief to prevent a rebound in these
processes after treatment discontinuation. Alternatively, since depression is a chronic illness
defined by a remitting-relapsing course, it is possible that patients with untreated or
undertreated relapses in depressive symptoms post-intervention may have particularly high
cardiovascular risk during those time-periods of symptom rebound. A better understanding
of the complex interactions between depression treatment, depressive symptoms, and the
biological and behavioral mediators of cardiac risk in patients with depression after an acute
coronary syndrome event is needed to better understand the “catch-up” phenomenon for
cardiac risk that we observed.
The current findings have several limitations, including the small study size and the post-hoc
nature of the analyses. Given the small number of events, it is possible that chance finding
or regression to the mean could explain the “catch-up” phenomenon we observed. In
addition, differential loss to follow-up due to a healthy survivor effect cannot be ruled out. It
is also unknown whether participants undertook cardiac rehabilitation or other activities that
could affect quality of life and cardiac risk during the treatment and follow-up time periods.
Furthermore, it is unknown what types of depression treatment, if any, were received by
participants during the observational follow-up. These findings are thus hypothesis-
generating and require replication. Nonetheless, our study raises the possibility that the
treatment of depression in patients with acute coronary syndromes may need to be of longer
duration to maintain the cardiac benefits observed during treatment. Future research is
needed to confirm our findings, to determine the optimal duration of initial depression
treatment in this patient population, and to identify treatment approaches that will deliver
durable results.
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• In the COPES trial, enhanced, patient-preference driven depression treatment
reduced cardiovascular events for patients with acute coronary syndromes and
comorbid depression during the 6-month treatment period
• During an additional 12 months of follow-up, we found that there was a rebound
in cardiovascular risk after treatment ended
• These results indicate a need to determine optimal duration of depression
treatment for patients with cardiovascular diseases and depression
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Title: Patient flowchart. BDI indicates Beck Depression Inventory.
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Title: Survival free from death or hospitalization for myocardial infarction or unstable
angina, by treatment assignment.
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Table 1
Baseline characteristics of participants in the Coronary Psychosocial Evaluation Studies randomized,
controlled trial, by treatment assignment.
Usual Care Group (n=77) Intervention Group (n=80) P value
Female, n (%) 41 (53) 43 (54) 0.95
Age, years (SD) 61.1 (10.6) 59.3 (10.6) 0.29
African American, n (%) 17 (22) 12(15) 0.25
Hispanic, n (%) 32 (42) 36(45) 0.66
Education (>= high school), n (%) 53 (73) 52(67) 0.43
Marital status, n (%)
        Single
        Married/partner








BDI>=16 at randomization, n (%) 52 (68) 52 (65) 0.74
Percutaneous coronary intervention at enrollment, n (%) 66 (86) 62(78) 0.19
Coronary artery bypass grafting at enrollment, n (%) 2 (3) 4 (5) 0.68
Globe Registry of Acute Coronary Events score, mean (SD) 94 (23) 92 (23) 0.58
Left Ventricular Ejection Fraction <40%, n (%) 13 (17) 17 (21) 0.49
Abbreviations: SD, standard deviation
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Table 2
Number (%) of participants with events, by treatment assignment and by time period.
Usual Care Group (n=77) Intervention Group (n=80)
During 6-month treatment period
    Death or major adverse cardiac event 11 (14%) 3 (4%)
    Death 1 (1%) 0 (0%)
    Major adverse cardiac event 11 (14%) 3 (4%)
During 12-month observational follow-up
    Death or major adverse cardiac event 3 (4%) 11 (14%)
    Death 1 (1%) 2 (3%)
    Major adverse cardiac event 2 (3%) 9 (11%)
Major adverse cardiac event is defined as hospitalization for myocardial infarction / unstable angina.
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